Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. [electronic resource]
Producer: 19990430Description: 1951-8 p. digitalISSN:- 1524-4539
- Abciximab
- Aged
- Angioplasty, Balloon, Coronary -- statistics & numerical data
- Antibodies, Monoclonal -- therapeutic use
- Biomarkers
- Cause of Death
- Combined Modality Therapy
- Coronary Artery Bypass -- statistics & numerical data
- Coronary Disease -- complications
- Creatine Kinase -- blood
- Double-Blind Method
- Drug Therapy, Combination
- Emergencies
- Female
- Follow-Up Studies
- Heparin -- administration & dosage
- Humans
- Immunoglobulin Fab Fragments -- therapeutic use
- Incidence
- Isoenzymes
- Male
- Middle Aged
- Myocardial Infarction -- mortality
- Myocardial Ischemia -- mortality
- Platelet Aggregation Inhibitors -- therapeutic use
- Platelet Glycoprotein GPIIb-IIIa Complex -- antagonists & inhibitors
- Prospective Studies
- Recurrence
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.